Journal of Immunology Research
Volume 2019 (2019), Article ID 1780567, 11 pages
https://doi.org/10.1155/2019/1780567

Research Article

Enhancement of the Soluble Form of OX40 and OX40L Costimulatory Molecules but Reduction of the Membrane Form in Type 1 Diabetes (T1D)

Jingnan An,1,2 Sisi Ding,³ Sicheng Li,⁴ Lili Sun,³ Xin Chang,¹ Ziyi Huang,¹ Bin Zhou,³ Chen Fang,⁴ Cuiping Liu,¹ and Xueguang Zhang³

¹Jiangsu Institute of Clinical Immunology, First Affiliated Hospital of Soochow University, Suzhou, China
²Institute of Blood and Marrow Transplantation, First Affiliated Hospital of Soochow University, Suzhou, China
³Jiangsu Key Laboratory of Clinical Immunology, First Affiliated Hospital of Soochow University, Suzhou, China
⁴Department of Endocrinology, Second Affiliated Hospital of Soochow University, Suzhou, China

Correspondence should be addressed to Chen Fang; afa9911@sina.com and Cuiping Liu; liucuiping1980@126.com

Received 12 December 2018; Revised 15 May 2019; Accepted 28 June 2019; Published 1 August 2019

Academic Editor: Ravirajsinh N. Jadeja

Copyright © 2019 Jingnan An et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

This study analyzed the expression of membrane OX40 and OX40L (mOX40 and mOX40L) and levels of soluble OX40 and OX40L (sOX40 and sOX40L) in T1D patients to determine their clinical significance. Peripheral blood (PB) was collected from patients with T1D and healthy control participants. Expression of mOX40 and mOX40L on immune cells was detected by flow cytometry. Levels of sOX40 and sOX40L in sera were measured by ELISA. We demonstrated for the first time enhanced sOX40 and sOX40L expression and reduced mOX40 and mOX40L levels in T1D patients which correlated with the clinical characteristics and inflammatory factors. These results suggest that OX40/OX40L signal may be promising biomarkers and associated with the pathogenesis of T1D.

1. Background

Type 1 diabetes (T1D) is a chronic and organ-specific autoimmune disease, is influenced by inherited or environmental factors, is increasing in all age groups, especially examined in children, and leads to the loss of insulin production in beta cells when immune cells invade the pancreatic islets [1–3]. The activation of T cells is mediated by antigen stimulation through T cell receptors and some costimulatory molecules. It has been suggested that CTLA-4 and PD-1 contribute to the development of T1D [4–6]. Multiple clinical immune intervention trials have been provided for the treatment of T1D such as blocking the costimulation of T cells [7–9]. However, the contributions of OX40 and OX40L to the development of T1D remain to be studied.

OX40/OX40L is a pair of important positive costimulatory signal molecules in the second signal system of T cells. OX40 (CD134) and OX40L (CD252), members of the TNF receptor superfamily (TNFRSF) and TNF superfamily (TNFSF), play important roles in T cell expansion in tumors, during infectious inflammation, and in autoimmune diseases [10, 11]. OX40 is expressed in activated T cells [12], while OX40L is mainly expressed in B lymphocytes, dendritic cells, and macrophage cells [12]. OX40/OX40L signaling acts as a key role in the development and differentiation of some immunological cells, especially T cells [13, 14]. Numerous studies have shown the important role of costimulatory molecules in T1D. Blocking costimulatory interactions such as CD28/B7 or CD40/CD40L might be an effective therapy way in NOD mice [15, 16]. Blocking OX40/OX40L interactions at the late age of disease may also suppress diabetes progression [17].

The level of sOX40 and sOX40L is elevated in some tumors and infectious diseases. This suggests that sOX40 and sOX40L act as costimulators to induce immune responses. However, to the best of our knowledge, the significance of membrane and soluble forms of OX40 or OX40L expression and their correlation with clinical parameters in T1D have not been investigated. To characterize OX40 and OX40L expression and determine the role of OX40/OX40L signal in the development and pathogenesis of T1D, we evaluated the expression of sOX40 and sOX40L in the PBMC and sera of patients with T1D and healthy controls (HCs) and analyzed the correlation with clinical and inflammatory indicators.

2. Materials and Methods

2.1. Patients and Controls

In our study, blood samples were collected after overnight fasting from patients () at the Endocrinology Department in the Second Affiliated Hospital of Soochow University, Suzhou, China, between 2015 and 2017. The diagnostic criteria for T1D were according to “The T1D Exchange Clinic Registry” [18]. Samples from healthy blood donors () were matched to T1D patients with age, gender, and race. In addition, HCs were tested for glucose levels, all T1D autoantibody negative. The study participants were excluded if they had one of the following conditions: acute or chronic inflammatory diseases, infectious diseases, and cancer. For the detection of membrane forms of OX40 and OX40L on immune cells, 46 patients and 44 HCs were enrolled. The approval from the Ethics Review Board of the Second Affiliated Hospital of Soochow University was granted to the patients.

2.2. Antibodies and Flow Cytometry

To assess the expression of mOX40 in CD3⁺, CD4⁺, or CD8⁺ T cells and mOX40L in CD14⁺ monocyte and CD19⁺ B cells, peripheral blood mononuclear cell (PBMC) was isolated from T1D patients or healthy donors. Flow cytometry was performed on PBMC incubated with fluorochrome-labeled monoclonal antibodies (mAbs) for 30 min. Anti-CD3-FITC (clone: UCHT1), anti-CD4-FITC (clone: RPA-T4), anti-CD8-FITC (clone: SFCI21), anti-CD14-FITC (clone: RMO52), and anti-CD19-FITC (clone: J3-119) mAbs were from Beckman Coulter. Anti-OX40-PE (clone: ACT35) and anti-OX40L-PE (clone: RM134L) were from eBioscience. Cells were washed and then immediately measured by flow cytometry (Beckman Coulter, CA). Data were analyzed using FlowJo software (Tree Star, OR).

2.3. Soluble OX40 and OX40L Measurement

The samples were centrifuged at 800xg for 8 min, and the sera was stored at -80°C for ELISA. To determine the relationship of sOX40 or sOX40L with the disease activity, serum levels of sOX40 and sOX40L were determined by ELISA using kits obtained from Kalang (Shanghai) and Cusabio (Wuhan), respectively. Sera samples were plated into the 96-well microplates, and ELISA was conducted following the manufacturer’s instructions. Plates were read in a microplate reader (Bio-Rad, CA) for the absorbance at 450 nm.

2.4. Cytokine Production

Cytokines interleukin IL-2, IL-4, IL-6, and IL-10, interferon gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and IL-17a were quantified in patients using a cytometric bead array system (CBA) (BD Pharmingen, CA) according to the instructions of the manufacturer. For each reaction, 50 μl sera were mixed with 50 μl beads to each assay tube. 50 μl PE detection reagent was then added, and the samples were incubated for 3 hours at room temperature. Samples were washed with wash buffer, centrifuged, and then run on flow cytometer; data were analyzed using BD™ CBA Software.

2.5. Statistical Analysis

Statistical analysis was performed using the IBM SPSS statistic 22 (Chicago, IL, USA). All the quantitative data was presented as the (SD). For statistical analysis, differences in continuous variables between two independent samples were evaluated by the Mann-Whitney test. Dichotomous variables were compared by the test. Association between continuous variables was assessed by means of Spearman and partial correlation. Pearson’s rank correlation analysis was used to evaluate the associations between dichotomous variables and protein levels. Covariance analysis was used. The statistical software GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA) and IBM SPSS statistic 22 (Chicago, IL, USA) were used for graph creation.

3. Results

3.1. Reduced mOX40 and mOX40L Expression in T1D Patients

The clinical characteristics of the study population are summarized in Table 1. To investigate the expression of mOX40 and mOX40L in T1D patients, blood specimens were collected from 46 T1D patients and 44 HCs. Flow cytometry analyses demonstrated that OX40 expression on CD3⁺, CD4⁺, and CD8⁺ T cells in PBMC samples was less frequent in patients with T1D than HCs ( vs. , ; vs. , ; and vs. , ; respectively) (Figures 1(a) and 1(b)). Furthermore, the expression of OX40L on CD14⁺ monocytes was also decreased significantly in PBMC samples of patients with T1D compared to HCs ( vs. , ). However, there was no significant difference in mOX40L on CD19⁺ B cells between T1D patients and HC ( vs. , ) (Figures 1(c) and 1(d)).

Table 1: Clinical features of the study population.

Type 1 diabetes ()
Healthy controls ()
valuea

Age (years)
28.5 (10-53)
29.4 (24-40)
0.75

Gender, female (%)
57 (47.9%)
51 (46.8%)
0.97

Duration (years)
7 (0-39)
—
—

Fasting venous blood glucose (mmol/l)
11.9 (3.99-22.3)
5.2 (3.8-6.4)
0.01

Cr (μmol/l)
54.2 (26-98)
82.3 (44-112)
0.04

BUN (mmol/l)
4.4 (1.4-8.4)
—
—

UA (μmol/l)
275.7 (81-540)
—
—

ALT (IU/l)
18.9 (2-92)
—
—

AST (IU/l)
20.0 (8-62)
—
—

TC (mmol/l)
4.4 (0.8-7.6)
—
—

TG (mmol/l)
1.1 (0.4-5.7)
—
—

LDL (mmol/l)
2.1 (1.1-5.4)
—
—

HDL (mmol/l)
1.4 (0.7-2.4)
—
—

Fasting C-peptide (ng/ml)
1.6 (<0.01-35)
—
—

Anti-ICA positive (%)b
11 (27%)
—
—

Anti-GAD positive (%)b
17 (41%)
—
—

Anti-IAA positive (%)b
3 (7%)
—
—

HbA1c (%)
9.12% (5.3-17.1%)
—
—

Ketosis
17 (41%)
—
—

IFN-γ (pg/ml)
1.5 (0-17.2)
—
—

IL-2 (pg/ml)
2.7 (0.4-11.9)
—
—

IL-4 (pg/ml)
2.1 (0-14.1)
—
—

IL-6 (pg/ml)
4.2 (0-15.6)
—
—

IL-10 (pg/ml)
4.7 (0.7-20.4)
—
—

TNF-α (pg/ml)
3.1 (0-17.2)
—
—

IFN-γ (pg/ml)
3.1 (0.4-19.3)
—
—

IL-17a (pg/ml)
26.0 (0-159.9)
—
—

a value is based on the statistical analysis by the Mann-Whitney test or the chi-square test assessing overall group differences. bNot all the patients have the antibody results, only 52/119 patients received an autoantibody screening. cAbbreviations: Cr: creatinine; BUN: urea; UA: uric acid; ALT: alanine aminotransferase; AST: aspartate transferase; TC: cholesterol; TG: triglycerides; LDL: low-density lipoprotein; HDL: high-density lipoprotein; IAA: insulin autoantibody.

(a)

(b)

(c)

(d)

Figure 1: Expression of mOX40 and its ligand mOX40L in the PBMC of T1D patients. (a) The expression level of mOX40 was detected by flow cytometry of CD3⁺, CD4⁺, and CD8⁺ T cells from T1D patients and HCs. (b) Percentages of CD3⁺OX40⁺, CD4⁺OX40⁺, and CD8⁺OX40⁺ cells in the PBMC samples of patients with T1D and HCs. (c) The expression level of mOX40L was detected by flow cytometry of monocyte cells from T1D patients and HCs. CD14 and CD19 were used as markers of monocytes and B cells. (d) A histogram representative of a set of CD14⁺OX40L⁺ and CD19⁺OX40L⁺ is shown in the right figure.

3.2. Correlation between mOX40 and mOX40L Positive Cells and Clinical Parameters of T1D

To determine whether the negative association of mOX40 and mOX40L expression is related to T1D disease activity, we examined the relationship between the presence of mOX40 and mOX40L and the disease state. The statistical analyses of the correlation between clinical features and the expression of mOX40 and mOX40L are presented in Table 2. We found that the expression of glutamic acid decarboxylase (GAD) was negatively correlated with CD8⁺OX40⁺ T cells (, ) and CD19⁺OX40L⁺ B cells (, ). A significant negative correlation between CD3⁺OX40⁺ T cells (, ), CD4⁺OX40⁺ T cells (, ), and creatinine (Cr) was observed; we also found a significant negative correlation between CD3⁺OX40⁺ T cells (, ) and CD4⁺OX40⁺ T cells (, ) with uric acid (UA). However, we did not found any correlation between CD8⁺OX40⁺ T cells and Cr or UA (Supplement Figure 1).

Table 2: Correlation between clinical features and membrane levels of OX40 and OX40L.

CD4⁺OX40⁺
CD8⁺OX40⁺
CD3⁺OX40⁺
CD19⁺OX40L⁺
CD14⁺OX40L⁺

Ketosis
0.2692
0.2257
0.1746
0.4301
0.2770
0.2121
-0.3000
0.1750
0.1307
0.5619

GAD
-0.0570
0.7818
-0.3996
0.0431
-0.0571
0.7816
-0.3789
0.0463
-0.1401
0.4948

ICA
-0.0121
0.9529
-0.1582
0.4401
-0.0365
0.8593
-0.0608
0.7677
0.1245
1.0042

IAA
0.1467
0.4746
-0.1467
0.4746
0.1735
0.3968
-0.0133
0.9485
-0.0933
0.6502

DKA
0.4468
0.0371
0.1043
0.6443
0.3725
0.0878
-0.0744
0.7419
-0.0148
0.9475

HDL
-0.3474
0.0555
-0.2594
0.1588
-0.3528
0.0516
-0.1488
0.4245
-0.1671
0.3689

LDL
-0.1773
0.3401
-0.1264
0.4979
-0.2231
0.2276
-0.1470
0.4300
-0.1408
0.4501

TC
-0.2280
0.2019
-0.2848
0.1081
-0.2739
0.1230
-0.1321
0.4638
-0.1053
0.5597

TG
0.3627
0.0380
0.0844
0.6404
0.2936
0.0973
0.2199
0.2189
0.1634
0.3637

ALT
-0.0560
0.7605
0.1015
0.5804
0.0540
0.7688
0.0421
0.8190
0.1166
0.5252

AST
0.0852
0.6426
0.2025
0.2663
0.2056
0.2591
0.0343
0.8519
0.0479
0.7943

LDH
0.0260
0.9107
0.0655
0.9978
0.1383
0.5500
0.0416
0.8576
0.1498
0.5168

GGT
-0.0510
0.8085
0.1969
0.3455
-0.1076
0.6086
0.0947
0.6522
-0.3137
0.1267

Cr
-0.4072
0.0187
-0.1674
0.9926
-0.3911
0.0244
0.0363
0.8410
-0.2899
0.1017

BUN
-0.2858
0.1069
-0.1345
0.4557
-0.2436
0.1719
0.1462
0.4170
-0.1055
0.5589

UA
-0.4231
0.0142
-0.6887
0.7033
-0.4357
0.0113
0.0885
0.6239
-0.3246
0.0653

GLU
0.1162
0.5802
-0.4501
0.8308
0.1328
0.5268
0.0076
0.9971
-0.0561
0.7897

C0
-0.1418
0.4238
-0.1189
0.5031
-0.2069
0.2404
-0.0207
0.9072
0.1722
0.3300

C120
-0.2638
0.2901
-0.1209
0.6328
-0.3487
0.1562
0.0830
0.7432
0.3595
0.1429

HbA1c
0.4666
0.0047
0.0926
0.5966
0.3930
0.0195
0.3994
0.0175
0.3332
0.0504

3.3. Higher Serum Levels of sOX40 and sOX40L in T1D Patients

Our previous work demonstrated that in addition to mOX40 and mOX40L, sOX40 and sOX40L are also present in human sera. Serum levels of sOX40 and sOX40L were determined by ELISA. As shown in Figure 2(a), the concentration of sOX40 in the sera of T1D patients was significantly higher than that of HCs ( vs. , ). Meanwhile, we found that the concentration of sOX40L was also significantly higher than that in HCs ( vs. , ) (Figure 2(b)). To explore whether sOX40 and sOX40L are involved in the development of T1D, we further analyzed the relationship between sOX40, sOX40L, and disease activity. We conducted a correlation analysis and found a positive correlation between sOX40 expression and UA (, ) and hemoglobin A1c (HbA1c) (, ), that is, T1D patients with higher sOX40 expression levels had higher UA and HbA1c (Figures 2(c) and 2(e)). The correlation between sOX40L and hemoglobin A1c (, ) was also positive but was not significant with UA (, ) (Figures 2(d) and 2(f)). These data suggest that the expression of sOX40 and sOX40L correlates with several parameters of disease activity. To evaluate whether OX40 and OX40L play a role in the process of T cell differentiation, we measured the serum levels of some cytokines such as IL-2, IL-4, IL-6, IL-10, IFN-γ, TNF-α, and IL-17a in T1D patients, finding no significant correlation between sOX40 expressions and cytokines (Table 3). However, sOX40L expression in T1D patients was positively correlated with serum levels of IL-2 (, ), IL-6 (, ), IL-10 (, ), and IFN-γ (, ) (Figure 3).

(a)

(b)

(c)

(d)

(e)

(f)

Figure 2: Correspondence correlation between sOX40 and sOX40L levels in HC blood and T1D disease. (a) Increased sOX40 was observed in the sera from T1D patients as compared to HCs. (b) Increased sOX40L levels were observed in the sera from patients with T1D compared with the HC group. (c) Positive correlation between sOX40 and the expression of UA. (d) No significant correlation between sOX40L and the expression of UA. (e) No significant correlation between sOX40 and the expression of HbA1c. (f) Positive correlation between sOX40L and the expression of HbA1c.

Table 3: Correlation between clinical features and soluble levels of OX40 and OX40L.

sOX40
sOX40L

Ketosis
0.2191
0.7217
-0.0344
0.8395

GAD
0.0289
0.3379
0.0840
0.4954

ICA
0.0070
0.7302
0.1846
0.1318

IAA
0.0607
0.7442
0.1463
0.2337

DKA
0.0962
0.6942
-0.0107
0.9448

HDL
0.1826
0.1159
-0.0511
0.6630

LDL
0.0733
0.7493
0.1849
0.1123

TC
0.0229
0.9884
0.1528
0.1846

TG
-0.0635
0.1745
0.0131
0.9094

ALT
-0.2506
0.7772
-0.1072
0.3632

AST
-0.1859
0.6487
-0.1434
0.2228

LDH
-0.2732
0.6829
-0.0224
0.8851

GGT
-0.0967
0.7239
-0.142
0.3253

Cr
-0.0148
0.5676
-0.1343
0.2443

BUN
-0.1330
0.1402
-0.0909
0.4317

UA
0.3376
0.0189
-0.1127
0.3323

GLU
0.1428
0.3729
0.0974
0.4627

C0
0.0398
0.4693
0.1008
0.3736

C120
0.2641
0.4974
0.1211
0.4952

HbA1c
0.3045
0.0616
0.3131
0.0001

CD4⁺OX40⁺ T
-0.3373
0.0225
—
—

CD8⁺OX40⁺ T
-0.4733
0.7018
—
—

CD3⁺OX40⁺ T
-0.3629
0.0162
—
—

CD19⁺OX40L⁺ B
—
—
0.2351
0.0683

CD14⁺OX40L⁺ monocyte
—
—
0.2499
0.0521

IL-2
0.2461
0.1137
0.3676
0.0252

IL-4
0.1455
0.1232
0.2422
0.1487

IL-6
0.0214
0.0196
0.3139
0.0485

IL-10
-0.1077
0.1482
0.3455
0.0362

TNF-α
0.4713
0.0569
0.1964
0.2448

IFN-γ
0.4238
0.0922
0.5201
0.0056

IL-17a
0.4947
0.0535
0.2291
0.1726

Figure 3: Correlation between sOX40 and sOX40L expression and sera cytokine levels in T1D patients. Positive correlation between sOX40L and the expression of IL-2, IL-6, IL-10, and IFN-γ.

3.4. Negative Correlation between Serum Levels of sOX40 and mOX40 in T1D Patients

Correlation analyses demonstrated that there was a significant negative association between serum OX40 levels and mOX40 expression on CD3⁺ T cells (, ) and CD4⁺ T cells (, ) in T1D patients (Figure 4). Although not significant, there was a negative association between sOX40 levels and mOX40 expression on CD8⁺ T cells (, ) (Table 3).

(a)

(b)

(c)

Figure 4: Correlation between serum levels of sOX40 and mOX40 in T1D patients. (a) Significant negative correlation between sOX40 and mOX40 expression on CD3⁺ T cells. (b) Significant negative correlation between sOX40L and mOX40 expression on CD4⁺ T cells. (c) Negative correlation between sOX40L and mOX40 expression on CD8⁺ T cells.

4. Discussion

Costimulatory molecules play important roles in regulation of the immune response in autoimmune diseases. Therefore, they may be useful as treatment indicators for the disease [19].

The TNF/TNFR family members of costimulatory molecules are critical in regulating T cell responses [20]. Here, we detected the expression of membrane and soluble forms of OX40 and OX40L on immune cells in T1D patients and determined their clinical significance. For the first time, we detected the membrane and soluble forms of OX40 and OX40L expression in the PBMC of T1D patients and analyzed the correlation with disease activity. We found that sOX40 and sOX40L expression in T1D patients was significantly higher compared with the HCs. However, the expression of mOX40 and mOX40L in T1D patients was significantly lower compared with that in HCs. There was no significant correlation of mOX40L of CD19⁺ B cells in T1D patients and HCs. In addition, sOX40 levels in patients were positively correlated with the disease activity, as indicated by T1D disease activity, and sOX40L levels in the patients were positively correlated with inflammatory cytokines. Our findings suggest that sOX40 and sOX40L might counteract the aberrant immune response and potentially serve as monitoring indicators of disease progression and therapeutic targets in T1D treatment.

Costimulatory molecules can induce the activation of T cells, promote cell survival, support the formation of potential memory T cells, and produce the release of the cytokines [21, 22]. Therefore, the costimulatory molecules may be useful for the diagnosis and treatment of some diseases. Both membrane and soluble forms of costimulatory molecules play important roles in the regulation of immune networks [23]. Costimulatory molecules with soluble forms could be generated from proteolytic cleavage, such as PD-L1, B7H3 [24], ICOS, and ICOSL [25], or could be generated from mRNA splicing like CTLA-4 [26] and PD-1 [27]. It has been found that sOX40 is expressed in patients with amyotrophic lateral sclerosis [28] and chronic lymphocytic leukemia [29], while sOX40L is expressed in the sera of patients with acute coronary syndrome, bronchial asthma (adult), Henoch-Schonlein purpura (children), and rheumatoid arthritis [30–33]. In our study, we observed relatively higher sOX40 and sOX40L levels but lower mOX40 and mOX40L in T1D patients, suggesting that sOX40 and sOX40L might have regulatory functions opposite to mOX40 and mOX40L. High levels of soluble molecule may be the consequence of two different processes, such as high production or decreased depletion. In T1D patients, we speculate that soluble levels increase because mOX40 and mOX40L are cleavaged into the soluble forms, leading to higher sOX40 and sOX40L expression in PBMC compared with the HCs.

Autoantibodies in T1D are risk indicators for the diagnosis and prediction of the disease and surrogate markers for autoimmune diabetes [34–37]. The presence of several autoantibodies such as islet cell autoantibody (ICA) and GAD indicates an autoimmune pathogenic response to beta cells [38]. We measured the membrane variants of OX40 and OX40L in T1D individuals, which were reduced compared to HC. Meanwhile, GAD expression is also associated with mOX40 and mOX40L expression. However, some other indicators such as higher levels of UA are also associated with enlarged risk of the clinical manifestations of diabetic nephropathy in persons with T1D [39, 40]. Moreover, HbA1c is the most common and widely accepted indicator of T1D [41–43]. In our study, we found that T1D patients with higher sOX40 expression levels had higher UA, and higher sOX40L expression levels had higher HbA1c, which means OX40 and OX40L are promising markers for T1D.

The detailed functions of some costimulatory molecules are still controversial. Until now, one of the most attractive approaches to prevent T1D is using islet antigen-specific regulatory T cells (Tregs). Luczynski et al. discovered that the mRNA level of OX40 was lower in Treg cells of children with T1D when compared to the reference patients [2]. However, Szypowska et al. observed that T1D children had higher frequency of CD4⁺CD25highOX40⁺ cells than healthy subjects [44]. In our study, we found a reduction of the membrane form of OX40 on CD3⁺, CD4⁺, and CD8⁺ T cells and a reduction of OX40L on CD14⁺ monocytes in T1D patients correlated with clinical parameters. Bresson et al. have found that OX40 agonist therapy can slow down T1D progression [45]. We speculate that increasing the level of OX40 may be a new therapeutic strategy.

5. Conclusions

Taken together, our study revealed the dissociation between mOX40 and mOX40L expression and sOX40 and sOX40L levels in T1D patients for the first time. We provided evidence for the diagnostic value of OX40 and OX40L in T1D patients. The abnormal expression of OX40 and OX40L molecules appears to be connected with the severity of the disease. Thus, OX40 and OX40L may be promising biomarkers for diagnosis and prognosis of T1D. The in-depth mechanisms of membrane and soluble OX40 and OX40L in T1D remain to be elucidated, and the role of OX40 and OX40L in immune pathogenesis of T1D requires further research.

Abbreviations

CBA: | Cytometric bead array
GAD: | Glutamic acid decarboxylase
HCs: | Healthy controls
HbA1c: | Hemoglobin A1c
IFN-γ: | Interferon gamma
ICA: | Islet cell autoantibody
mAbs: | Monoclonal antibodies
PBMC: | Peripheral blood mononuclear cells
SD: | Standard deviation
T1D: | Type 1 diabetes
TNFRSF: | TNF receptor superfamily
TNFSF: | TNF superfamily
TNF-α: | Tumor necrosis factor-alpha
Tregs: | Antigen-specific regulatory T cells
UA: | Uric acid.

Data Availability

The data used to support the findings of this study are available from the corresponding authors upon request.

Ethical Approval

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the 1975 Declaration of Helsinki, as revised in 2008. This article does not contain any studies with human or animal subjects performed by any of the authors.

Consent

Informed consent was obtained from all patients being included in the study.

Conflicts of Interest

The authors declare that they have no conflict of interest.

Authors’ Contributions

Jingnan An and Sisi Ding equally contributed to the study.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (grants 81873876, 81600607, 81502454, and 81701596), the Jiangsu Provincial Medical Youth Talent (No. QNRC2016755 and No. QNRC2016770), the Science and Technology Project of Suzhou (No. SYS201740), and the Natural Science Foundation of Jiangsu Province (No. BK20160349).

Supplementary Materials

Supplement Figure 1: correlation between CD3⁺OX40⁺, CD4⁺OX40⁺, and CD8⁺OX40⁺ and clinic pathological characteristics. Negative correlation between CD3⁺OX40⁺ and CD4⁺OX40⁺ and the expression of UA and Cr. No correlation between CD8⁺OX40⁺ and the expression of UA and Cr. (Supplementary Materials)

References

M. Battaglia, L. Nigi, and F. Dotta, “Towards an earlier and timely diagnosis of type 1 diabetes: is it time to change criteria to define disease onset?” Current Diabetes Reports, vol. 15, no. 12, p. 115, 2015.

W. Łuczyński, A. Stasiak-Barmuta, A. Juchniewicz et al., “The mRNA expression of pro- and anti-inflammatory cytokines in T regulatory cells in children with type 1 diabetes,” Folia Histochemica et Cytobiologica, vol. 48, no. 1, pp. 93–100, 2010.

J. A. Janzen Claude, H. D. Hadjistavropoulos, and L. Friesen, “Exploration of health anxiety among individuals with diabetes: prevalence and implications,” Journal of Health Psychology, vol. 19, no. 2, pp. 312–322, 2014.

F. Zouidi, M. Stayoussef, D. Bouzid et al., “Contribution of PTPN22, CD28, CTLA-4 and ZAP-70 variants to the risk of type 1 diabetes in Tunisians,” Gene, vol. 533, no. 1, pp. 420–426, 2014.

M. L. Colli, J. L. E. Hill, L. Marroquí et al., “PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-α and-γ via IRF1 induction,” EBioMedicine, vol. 36, pp. 367–375, 2018.

S. Momin, S. Flores, B. Angel B, E. Codner D, E. Carrasco P, and F. Perez-Bravo, “Interactions between programmed death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) gene polymorphisms in type 1 diabetes,” Diabetes Research and Clinical Practice, vol. 83, no. 3, pp. 289–294, 2009.

B. Nambam and M. J. Haller, “Updates on immune therapies in type 1 diabetes,” European Endocrinology, vol. 12, no. 2, pp. 89–95, 2016.

T. Orban, B. Bundy, D. J. Becker et al., “Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 378, no. 9789, pp. 412–419, 2011.

T. Orban, B. Bundy, D. J. Becker et al., “Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment,” Diabetes Care, vol. 37, no. 4, pp. 1069–1075, 2014.

W. Lei, D. Zeng, G. Liu et al., “Crucial role of OX40/OX40L signaling in a murine model of asthma,” Molecular Medicine Reports, vol. 17, no. 3, pp. 4213–4220, 2018.

G. J. Webb, G. M. Hirschfield, and P. J. L. Lane, “OX40, OX40L and autoimmunity: a comprehensive review,” Clinical Reviews in Allergy & Immunology, vol. 50, no. 3, pp. 312–332, 2016.

M. Karulf, A. Kelly, A. D. Weinberg, and J. A. Gold, “OX40 ligand regulates inflammation and mortality in the innate immune response to sepsis,” The Journal of Immunology, vol. 185, no. 8, pp. 4856–4862, 2010.

W. Lei, D. X. Zeng, C. H. Zhu et al., “The upregulated expression of OX40/OX40L and their promotion of T cells proliferation in the murine model of asthma,” Journal of Thoracic Disease, vol. 6, no. 7, pp. 979–987, 2014.

M. M. Cavanagh and T. Hussell, “Is it wise to target the late costimulatory molecule OX40 as a therapeutic target?” Archivum Immunologiae et Therapiae Experimentalis, vol. 56, no. 5, pp. 291–297, 2008.

J. Irie, Y. Wu, K. Kachapati, R. S. Mittler, and W. M. Ridgway, “Modulating protective and pathogenic CD4⁺ subsets via CD137 in type 1 diabetes,” Diabetes, vol. 56, no. 1, pp. 186–196, 2007.

D. J. Lenschow, S. C. Ho, H. Sattar et al., “Differential effects of anti-b7-1 and anti-b7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse,” Journal of Experimental Medicine, vol. 181, no. 3, pp. 1145–1155, 1995.

C. S. Haddad, P. Bhattacharya, K. Alharshawi et al., “Age-dependent divergent effects of OX40L treatment on the development of diabetes in nod mice,” Autoimmunity, vol. 49, no. 5, pp. 298–311, 2016.

R. W. Beck, W. V. Tamborlane, R. M. Bergenstal et al., “The T1D exchange clinic registry,” The Journal of Clinical Endocrinology & Metabolism, vol. 97, no. 12, pp. 4383–4389, 2012.

M. L. Ford, A. B. Adams, and T. C. Pearson, “Targeting co-stimulatory pathways: transplantation and autoimmunity,” Nature Reviews Nephrology, vol. 10, no. 1, pp. 14–24, 2014.

G. P. Doss, G. Agoramoorthy, and C. Chakraborty, “TNF/TNFR: drug target for autoimmune diseases and immune-mediated inflammatory diseases,” Frontiers in Bioscience, vol. 19, no. 7, pp. 1028–1040, 2014.

D. H. Wagner Jr., “Overlooked mechanisms in type 1 diabetes etiology: how unique costimulatory molecules contribute to diabetogenesis,” Frontiers in Endocrinology, vol. 8, p. 208, 2017.

T. Maj, S. Wei, T. Welling, and W. Zou, “T cells and costimulation in cancer,” The Cancer Journal, vol. 19, no. 6, pp. 473–482, 2013.

H. Bour-Jordan and J. A. Bluestone, “Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells,” Immunological Reviews, vol. 229, no. 1, pp. 41–66, 2009.

G. Zhang, J. Hou, J. Shi, G. Yu, B. Lu, and X. Zhang, “Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated t cells and is detectable in normal human serum,” Immunology, vol. 123, no. 4, pp. 538–546, 2008.

X. Hu, J. Wu, J. An et al., “Development of a novel monoclonal antibody to human inducible co-stimulator ligand (ICOSL): biological characteristics and application for enzyme-linked immunosorbent assay,” International Immunopharmacology, vol. 36, pp. 151–157, 2016.

G. Magistrelli, P. Jeannin, N. Herbault et al., “A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells,” European Journal of Immunology, vol. 29, no. 11, pp. 3596–3602, 1999.

C. Nielsen, L. Ohm-Laursen, T. Barington, S. Husby, and S. T. Lillevang, “Alternative splice variants of the human PD-1 gene,” Cellular Immunology, vol. 235, no. 2, pp. 109–116, 2005.

J. Ilzecka, “Serum soluble OX40 in patients with amyotrophic lateral sclerosis,” Acta Clinica Croatica, vol. 51, no. 1, pp. 3–7, 2012.

L. Taylor and H. Schwarz, “Identification of a soluble OX40 isoform: development of a specific and quantitative immunoassay,” Journal of Immunological Methods, vol. 255, no. 1-2, pp. 67–72, 2001.

W. Lei, C. H. Zhu, X. W. Q. Zeng da et al., “SOX40L: an important inflammatory mediator in adult bronchial asthma,” Annals of the Academy of Medicine, Singapore, vol. 41, no. 5, pp. 200–204, 2012.

J. Yan, J. Gong, G. Chen, P. Liu, C. Wang, and P. Yang, “Evaluation of serum soluble OX40 ligand as a prognostic indicator in acute coronary syndrome patients,” Clinica Chimica Acta, vol. 411, no. 21-22, pp. 1662–1665, 2010.

J. K. Laustsen, T. K. Rasmussen, K. Stengaard-Pedersen et al., “Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis,” Arthritis Research & Therapy, vol. 16, no. 5, p. 474, 2014.

W. Qin, W. Hongya, C. Yongjing et al., “Increased OX40 and soluble OX40 ligands in children with Henoch-Schonlein purpura: association with renal involvement,” Pediatric Allergy and Immunology, vol. 22, no. 1, Part I, pp. 54–59, 2011.

J. M. Wenzlau and J. C. Hutton, “Novel diabetes autoantibodies and prediction of type 1 diabetes,” Current Diabetes Reports, vol. 13, no. 5, pp. 608–615, 2013.

L. Yu, Z. Zhao, and A. K. Steck, “T1D autoantibodies: room for improvement?” Current Opinion in Endocrinology & Diabetes and Obesity, vol. 24, no. 4, pp. 285–291, 2017.

V. Lampasona and D. Liberati, “Islet autoantibodies,” Current Diabetes Reports, vol. 16, no. 6, p. 53, 2016.

G. Fousteri, E. Ippolito, R. Ahmed, and A. Rahim Hamad, “Beta-cell specific autoantibodies: are they just an indicator of type 1 diabetes?” Current Diabetes Reviews, vol. 13, no. 3, pp. 322–329, 2017.

A. Lounici Boudiaf, D. Bouziane, M. Smara et al., “Could ZnT8 antibodies replace ICA, GAD, IA2 and insulin antibodies in the diagnosis of type 1 diabetes?” Current Research in Translational Medicine, vol. 66, no. 1, pp. 1–7, 2018.

M. Mauer and A. Doria, “Uric acid and diabetic nephropathy risk,” Contributions to Nephrology, vol. 192, pp. 103–109, 2018.

P. Hovind, P. Rossing, L. Tarnow, R. J. Johnson, and H. H. Parving, “Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study,” Diabetes, vol. 58, no. 7, pp. 1668–1671, 2009.

Y. Huang, S. C. Li, J. Hu et al., “Gut microbiota profiling in Han Chinese with type 1 diabetes,” Diabetes Research and Clinical Practice, vol. 141, pp. 256–263, 2018.

D. Ruiz-Aranda, L. Zysberg, E. García-Linares, A. M. Castellano-Guerrero, M. A. Martínez-Brocca, and M. R. Gutiérrez-Colosía, “Emotional abilities and HbA1c levels in patients with type 1 diabetes,” Psychoneuroendocrinology, vol. 93, pp. 118–123, 2018.

K. Nirantharakumar, N. Mohammed, K. A. Toulis, G. N. Thomas, and P. Narendran, “Clinically meaningful and lasting HbA1c improvement rarely occurs after 5 years of type 1 diabetes: an argument for early, targeted and aggressive intervention following diagnosis,” Diabetologia, vol. 61, no. 5, pp. 1064–1070, 2018.

A. Szypowska, A. Stelmaszczyk-Emmel, U. Demkow, and W. Łuczyński, “High expression of OX40 (CD134) and 4-1BB (CD137) molecules on CD4⁺CD25high cells in children with type 1 diabetes,” Advances in Medical Sciences, vol. 59, no. 1, pp. 39–43, 2014.

D. Bresson, G. Fousteri, Y. Manenkova, M. Croft, and M. von Herrath, “Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment,” Journal of Autoimmunity, vol. 37, no. 4, pp. 342–351, 2011.